The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 02, 2006
Filed:
Dec. 03, 2002
John M. Nuss, Danville, CA (US);
Stephen D. Harrison, Berkeley, CA (US);
David B. Ring, Palo Alto, CA (US);
Rustum S. Boyce, San Francisco, CA (US);
Sean P. Brown, Emeryville, CA (US);
Dane A. Goff, Redwood City, CA (US);
Kirk W. Johnson, Moraga, CA (US);
Keith B. Pfister, El Cerrito, CA (US);
Savithri Ramurthy, Walnut Creek, CA (US);
Paul A. Renhowe, Danville, CA (US);
Lynn Seely, Burlingame, CA (US);
Sharadha Subramanian, San Ramon, CA (US);
Allan S. Wagman, Oakland, CA (US);
Xiaohui A. Zhou, Berkeley, CA (US);
John M. Nuss, Danville, CA (US);
Stephen D. Harrison, Berkeley, CA (US);
David B. Ring, Palo Alto, CA (US);
Rustum S. Boyce, San Francisco, CA (US);
Sean P. Brown, Emeryville, CA (US);
Dane A. Goff, Redwood City, CA (US);
Kirk W. Johnson, Moraga, CA (US);
Keith B. Pfister, El Cerrito, CA (US);
Savithri Ramurthy, Walnut Creek, CA (US);
Paul A. Renhowe, Danville, CA (US);
Lynn Seely, Burlingame, CA (US);
Sharadha Subramanian, San Ramon, CA (US);
Allan S. Wagman, Oakland, CA (US);
Xiaohui A. Zhou, Berkeley, CA (US);
Chiron Corporation, Emeryville, CA (US);
Abstract
New pyrimidine or pyridine based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as in the treatment of diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.